In last trading session, Xilio Therapeutics Inc (NASDAQ:XLO) saw 1.0 million shares changing hands with its beta currently measuring -0.15. Company’s recent per share price level of $0.80 trading at -$0.05 or -5.88% at ring of the bell on the day assigns it a market valuation of $41.42M. That closing price of XLO’s stock is at a discount of -112.5% from its 52-week high price of $1.70 and is indicating a premium of 22.5% from its 52-week low price of $0.62.
For Xilio Therapeutics Inc (XLO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.50. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.
Xilio Therapeutics Inc (NASDAQ:XLO) trade information
Upright in the red during last session for losing -5.88%, in the last five days XLO remained trading in the green while hitting it’s week-highest on Tuesday, 05/13/25 when the stock touched $0.80 price level, adding 32.2% to its value on the day. Xilio Therapeutics Inc’s shares saw a change of -16.23% in year-to-date performance and have moved 11.11% in past 5-day. Xilio Therapeutics Inc (NASDAQ:XLO) showed a performance of 12.36% in past 30-days.
Wall Street analysts have assigned a consensus price target of 7 to the stock, which implies a rise of 88.57% to its current value. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 7. It follows that stock’s current price would drop -775.0% in reaching the projected high whereas dropping to the targeted low would mean a loss of -775.0% for stock’s current value.
Xilio Therapeutics Inc (XLO) estimates and forecasts
This year revenue growth is estimated to rise 295.65% from the last financial year’s standing.
1 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 7.4M for the same. And 1 analysts are in estimates of company making revenue of 7.4M in the next quarter. Company posted 2.36M and 2.26M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -11.55% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 44.04% while estimates for its earnings growth in next 5 years are of -4.67%.
Xilio Therapeutics Inc (NASDAQ:XLO)’s Major holders
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC is the top institutional holder at XLO for having 3.79 million shares of worth $3.59 million. And as of 2024-06-30, it was holding 13.5618 of the company’s outstanding shares.
The second largest institutional holder is ROCK SPRINGS CAPITAL MANAGEMENT LP, which was holding about 3.0 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.7595 of outstanding shares, having a total worth of $2.85 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024, the former fund manager was holding 739.56 shares of worth $0.59 million or 1.43% of the total outstanding shares. The later fund manager was in possession of 190.94 shares on Mar 31, 2025, making its stake of worth around $0.15 million in the company or a holder of 0.37% of company’s stock.
